Company intelligence / Profile preview
4Moving Biotech
Lille, France4movingbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
4Moving Biotech has completed a Phase 1 study evaluating the safety and tolerability of 4P004 in osteoarthritis patients. The company is now conducting a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial called INFLAM MOTION across the EU, US, and Canada to evaluate the efficacy of 4P004 in individuals with knee osteoarthritis. The trial will enroll 129 patients and is expected to have the first patient enrolled in the second quarter of 2025.[5][6]
- Therapeutic areas
- Rheumatology
- Modalities
- GLP-1 analogPeptide
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on 4Moving Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4Moving Biotech.